TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19142901

Group type: EXPERIMENTAL
Intervention: Aggressive lymphadenectomy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 0

Group type: COMPARATOR
Intervention: Randomized controlled trials
Number of subjects: 0
Study: 17786799

Group type: EXPERIMENTAL
Intervention: Group A (broad multiphasic screening + normal consultation)
Number of subjects: 2000

Group type: EXPERIMENTAL
Intervention: Group B (broad multiphasic screening + fixed appointments for health consultations)
Number of subjects: 2000

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 2000
Study: 14615877

Group type: EXPERIMENTAL
Intervention: Ziprasidone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 0
Study: 10678970

Group type: EXPERIMENTAL
Intervention: SPA-TT(1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SPA-TT(2)
Number of subjects: 0
Study: 9066317

Group type: EXPERIMENTAL
Intervention: Intrathecal sufentanil (10 micrograms) plus bupivacaine (2.5 mg) plus epinephrine (0.2 mg)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Intrathecal sufentanil (10 micrograms) plus bupivacaine (2.5 mg) plus normal saline (control)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group (normal saline)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: EPI group (epinephrine)
Number of subjects: 39
Study: 1533168

Group type: EXPERIMENTAL
Intervention: Sufentanil (S) 4 micrograms/kg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Sufentanil-flunitrazepam (SF) 4 micrograms/kg of S and 40 micrograms/kg of flunitrazepam
Number of subjects: 20
Study: 3872228

Group type: EXPERIMENTAL
Intervention: Spectacles with 2x magnification
Number of subjects: 0
Study: 31499240

Group type: EXPERIMENTAL
Intervention: AAR + counseling
Number of subjects: 327

Group type: COMPARATOR
Intervention: AAR + control
Number of subjects: 327
Study: 29750549

Group type: EXPERIMENTAL
Intervention: Light-intensity walking (intervention)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Sitting interrupted with light-intensity walking (intervention)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Sitting condition (control)
Number of subjects: 6
Study: 27295867

Group type: EXPERIMENTAL
Intervention: 5% calcium sodium phosphosilicate (CSPS) toothpaste
Number of subjects: 134

Group type: COMPARATOR
Intervention: 0% CSPS toothpaste (placebo)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Commercial fluoride toothpaste 1
Number of subjects: 134

Group type: COMPARATOR
Intervention: Commercial fluoride toothpaste 2
Number of subjects: 134
Study: 26060460

Group type: EXPERIMENTAL
Intervention: Free conjunctival autotransplant (CAT)
Number of subjects: 190

Group type: COMPARATOR
Intervention: Limbal conjunctival autotransplant (LCAT)
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Age <50 years (young)
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Large pre-operative pterygium (grade ≥3)
Number of subjects: 190
Study: 21987279

Group type: EXPERIMENTAL
Intervention: Absorbable 4‐0 Vicryl Rapide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-absorbable 4‐0 Novafil
Number of subjects: 0
Study: 20433999

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin nadroparin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 19229379

Group type: EXPERIMENTAL
Intervention: Oral ketoprofen (300 mg)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Oral paracetamol (4 g)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 15993627

Group type: EXPERIMENTAL
Intervention: Equal interval and force (600 ms intervals, 12 N force)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Alternating interval and force (400, 800 ms intervals, 8, 16 N forces)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Alternating interval
Number of subjects: 13
Study: 12867249

Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 10826908

Group type: EXPERIMENTAL
Intervention: Ceftazidime
Number of subjects: 30

Group type: COMPARATOR
Intervention: Aztreonam
Number of subjects: 30
Study: 8682521

Group type: EXPERIMENTAL
Intervention: Cross-training, low workload
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Cross-training, high workload
Number of subjects: 80

Group type: COMPARATOR
Intervention: No cross-training, low workload
Number of subjects: 80

Group type: COMPARATOR
Intervention: No cross-training, high workload
Number of subjects: 80
Study: 1832372

Group type: EXPERIMENTAL
Intervention: Salbutamol (200 micrograms)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (40 micrograms)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate (2 mg)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Aerosol pentamidine (60 mg)
Number of subjects: 53
Study: 463806

Group type: EXPERIMENTAL
Intervention: Natural orange juice (80 mg of ascorbic acid daily)
Number of subjects: 362

Group type: EXPERIMENTAL
Intervention: Synthetic orange juice (80 mg of ascorbic acid daily)
Number of subjects: 362

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 362
Study: 30621513

Group type: EXPERIMENTAL
Intervention: HAL‐RAR
Number of subjects: 40

Group type: COMPARATOR
Intervention: EH
Number of subjects: 40
Study: 27426042

Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo (simulated LLLT applications)
Number of subjects: 54
Study: 25891297

Group type: EXPERIMENTAL
Intervention: POST-RENAL study participants
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: POST-RENAL study participants after age and sex matching
Number of subjects: 282
Study: 23450052

Group type: EXPERIMENTAL
Intervention: PCOS women with lower insulin sensitivity index (Si)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: PCOS women
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control women
Number of subjects: 28
Study: 21684088

Group type: EXPERIMENTAL
Intervention: Multidimensional Family Therapy (MDFT)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Both MDFT and CBT
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: MDFT
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: High problem severity subgroups
Number of subjects: 109
Study: 18295859

Group type: EXPERIMENTAL
Intervention: ZITI‐2000
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: BRAT 2
Number of subjects: 24
Study: 17386281

Group type: EXPERIMENTAL
Intervention: Femtosecond laser flap creation
Number of subjects: 1

Group type: COMPARATOR
Intervention: Mechanical microkeratome (not separated due to complication)
Number of subjects: 1
Study: 16642421

Group type: EXPERIMENTAL
Intervention: Protected alendronate 70 mg/day
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Standard alendronate 70 mg/day
Number of subjects: 78

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study: 14639802

Group type: EXPERIMENTAL
Intervention: n‐3 and n‐6 LCP‐enriched formula (A)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Standard formula (B)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Breast milk (control group)
Number of subjects: 31
Study: 10073783

Group type: EXPERIMENTAL
Intervention: 20 mg/day of quinapril
Number of subjects: 1750

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1750
Study: 7554971

Group type: EXPERIMENTAL
Intervention: 20 micrograms ethinylestradiol (EE) + 150 micrograms desogestrel (group A)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: 35 micrograms ethinylestradiol (EE) + 250 micrograms norgestimate (group B)
Number of subjects: 65
Study: 2109002

Group type: EXPERIMENTAL
Intervention: Prostacyclin (PGI2) at 4 ng/kg/min
Number of subjects: 8

Group type: COMPARATOR
Intervention: Diluent (glycine buffer)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Prostacyclin (PGI2)
Number of subjects: 8
Study: 6160322

Group type: EXPERIMENTAL
Intervention: Metoprolol (10 mg IV)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Propranolol (10 mg IV)
Number of subjects: 6
Study: 31889358

Group type: EXPERIMENTAL
Intervention: VR-Rollercoaster
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: VR-Ocean Rift
Number of subjects: 136

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 136
Study: 30015735

Group type: EXPERIMENTAL
Intervention: Orthognathic surgery with intended manual condylar positioning
Number of subjects: 18
Study: 27624287

Group type: EXPERIMENTAL
Intervention: 6 months clopidogrel
Number of subjects: 1601

Group type: EXPERIMENTAL
Intervention: 12 months clopidogrel
Number of subjects: 1601
Study: 24329913

Group type: EXPERIMENTAL
Intervention: Lamivudine 100 mg/day
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 22095209

Group type: EXPERIMENTAL
Intervention: Computerized complex movement training (track group)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Simple movement training (move group)
Number of subjects: 16
Study: 20696070

Group type: EXPERIMENTAL
Intervention: internet-based, tailored safety information combined with personal counselling
Number of subjects: 0

Group type: COMPARATOR
Intervention: personal counselling using the Safety Information Leaflets
Number of subjects: 0
Study: 18797697

Group type: EXPERIMENTAL
Intervention: Rosuvastatin (10 mg a day, orally)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 15736995

Group type: EXPERIMENTAL
Intervention: Nine-valent pneumococcal conjugate vaccine
Number of subjects: 0
Study: 12432338

Group type: COMPARATOR
Intervention: Placebo (n=15)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: 5 mg/day tamoxifen (n=16)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: 10 mg/day tamoxifen (n=16)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: 20 mg/day tamoxifen (n=15)
Number of subjects: 62
Study: 10525131

Group type: EXPERIMENTAL
Intervention: LDL-apheresis (LA) combined with simvastatin 40 mg per day
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: LDL-apheresis (LA)
Number of subjects: 12
Study: 8624230

Group type: EXPERIMENTAL
Intervention: Oscillating/rotating brush (Braun Oral‐B Plaque Remover)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Sonic toothbrush (Sonicare)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Manual brush (Crest Complete)
Number of subjects: 24
Study: 2373273

Group type: EXPERIMENTAL
Intervention: Pirenzepine
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Atropine
Number of subjects: 6

Group type: COMPARATOR
Intervention: Physiological saline
Number of subjects: 6
Study: 7400475

Group type: EXPERIMENTAL
Intervention: Oral theophylline solution
Number of subjects: 16

Group type: COMPARATOR
Intervention: Rectal theophylline solution
Number of subjects: 16
Study: 31067489

Group type: EXPERIMENTAL
Intervention: Mnemonic strategy training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (matched for stimulus exposure)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mnemonic strategy training (aMCI patients and healthy controls)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (exposure condition)
Number of subjects: 0
Study: 30088266

Group type: EXPERIMENTAL
Intervention: AuraGain™ laryngeal mask
Number of subjects: 44

Group type: COMPARATOR
Intervention: i-gel™ laryngeal mask
Number of subjects: 44
Study: 26842543

Group type: EXPERIMENTAL
Intervention: Air abrasive with glycine powder (AAD)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Manual debridement and chlorhexidine (MDA)
Number of subjects: 46
Study: 24969812

Group type: EXPERIMENTAL
Intervention: Concentric training
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Eccentric training
Number of subjects: 13
Study: 23506128

Group type: EXPERIMENTAL
Intervention: Foley catheter
Number of subjects: 1860

Group type: COMPARATOR
Intervention: Oral misoprostol (50 mcg every 4 hours)
Number of subjects: 1860
Study: 21254008

Group type: EXPERIMENTAL
Intervention: Elective laparoscopic cholecystectomy with on-table cholangiography (OTC)
Number of subjects: 190

Group type: COMPARATOR
Intervention: Elective laparoscopic cholecystectomy alone
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Elective laparoscopic cholecystectomy with OTC
Number of subjects: 190
Study: 19668097

Group type: EXPERIMENTAL
Intervention: Office-based vergence/accommodative therapy (OBVAT)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Home-based pencil push-ups (HBPP)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Home-based computer vergence/accommodative therapy and pencil push-ups (HBCVAT+)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Office-based placebo therapy (OBPT)
Number of subjects: 79
Study: 17902524

Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol (50 micrograms every 4-6 hours, max six doses)
Number of subjects: 310

Group type: COMPARATOR
Intervention: Oral misoprostol (50 micrograms every 4-6 hours, max six doses)
Number of subjects: 310

Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol
Number of subjects: 310

Group type: COMPARATOR
Intervention: Oral misoprostol
Number of subjects: 310
Study: 15316570

Group type: EXPERIMENTAL
Intervention: Blood alcohol concentration (BAC) of 0.04
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Blood alcohol concentration (BAC) of 0.08
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 10695818

Group type: EXPERIMENTAL
Intervention: Testicular irradiation after positive biopsy results
Number of subjects: 199

Group type: COMPARATOR
Intervention: Negative biopsy results (no testicular irradiation)
Number of subjects: 199
Study: 9235216

Group type: EXPERIMENTAL
Intervention: Combined phenibut (0.25 g) with obsidan (0.08 g)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bemethyl (0.5 g)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Phenibut (0.25 g)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Obsidian (0.08 g)
Number of subjects: 0
Study: 8444102

Group type: EXPERIMENTAL
Intervention: Halofantrin (three doses of 500 mg)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Halofantrin (one-day therapy)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Halofantrin
Number of subjects: 96
Study: 3028964

Group type: EXPERIMENTAL
Intervention: Non-absorbable antimicrobial drugs (polymyxin and neomycin)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Polymyxin and co-trimoxazole
Number of subjects: 100
Study: 31164006

Group type: EXPERIMENTAL
Intervention: Chronic schizophrenia
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Treatment-resistant schizophrenia
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: First-episode psychosis
Number of subjects: 270

Group type: COMPARATOR
Intervention: Healthy control groups
Number of subjects: 270
Study: 30425195

Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 mg BID
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 mg BID
Number of subjects: 218

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Tofacitinib (5 mg or 10 mg BID)
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Tofacitinib
Number of subjects: 218
Study: 27580103

Group type: EXPERIMENTAL
Intervention: Tilmicosin (20 mg/kg, SC) once at dry off
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Tilmicosin (20 mg/kg, SC) twice (once at dry off and again 20 days later)
Number of subjects: 172

Group type: COMPARATOR
Intervention: Ceftiofur (500 mg/mammary gland) at dry off
Number of subjects: 172
Study: 24885729

Group type: EXPERIMENTAL
Intervention: Family Healthy Lifestyle plus Family Recreation service integration (Comprehensive)
Number of subjects: 1168

Group type: EXPERIMENTAL
Intervention: Family Healthy Lifestyle service integration
Number of subjects: 1168

Group type: EXPERIMENTAL
Intervention: Family Recreation service integration
Number of subjects: 1168

Group type: COMPARATOR
Intervention: Existing services
Number of subjects: 1168
Study: 22545565

Group type: EXPERIMENTAL
Intervention: Real-time biofeedback
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham biofeedback
Number of subjects: 0

Group type: COMPARATOR
Intervention: Comparison of DPD patients and healthy volunteers
Number of subjects: 0
Study: 21279932

Group type: EXPERIMENTAL
Intervention: 20 mg Atorvastatin daily for 6 months
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: 40 mg Atorvastatin daily for 6 months
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: 80 mg Atorvastatin daily for 6 months
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: High-dose atorvastatin therapy
Number of subjects: 52
Study: 18359821

Group type: EXPERIMENTAL
Intervention: Topical glyceryl trinitrate (GTN) therapy with physical therapy
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard nonoperative physical therapy
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Topical glyceryl trinitrate (GTN) therapy
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard nonoperative therapy
Number of subjects: 40
Study: 16238586

Group type: EXPERIMENTAL
Intervention: Dpt specific immunotherapy (IT)
Number of subjects: 60
Study: 12030918

Group type: EXPERIMENTAL
Intervention: GHRP-2 + TRH + GnRH infusion
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: GHRP-2 + TRH infusion
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: GHRP-2 infusion
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33

Group type: COMPARATOR
Intervention: GHRP-2 alone
Number of subjects: 33
Study: 10720964

Group type: EXPERIMENTAL
Intervention: Low animal protein diet (< 10% of total energy)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: High-fiber diet (> 25 g/day)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Usual diet (control group)
Number of subjects: 96
Study: 18476119

Group type: EXPERIMENTAL
Intervention: Butoconazole nitrate 2% cream for 3 days
Number of subjects: 398

Group type: COMPARATOR
Intervention: Miconazole nitrate 2% cream for 7 days
Number of subjects: 398
Study: 1593018

Group type: EXPERIMENTAL
Intervention: Human alpha leukocyte interferon (IFN) 50,000 IU, 1 ml, twice a week for 4-6 weeks
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Human alpha leukocyte interferon (IFN) 50,000 IU, 1 ml, twice a week for 4-6 weeks + IL-2
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (uninjected nodule)
Number of subjects: 20
Study: 4041688

Group type: EXPERIMENTAL
Intervention: Family management based on behavioural family therapy
Number of subjects: 36

Group type: COMPARATOR
Intervention: Patient oriented management with family support
Number of subjects: 36
Study: 31927716

Group type: EXPERIMENTAL
Intervention: ABP 980 (KANJINTI™)
Number of subjects: 725

Group type: COMPARATOR
Intervention: trastuzumab RP (Herceptin®)
Number of subjects: 725

Group type: COMPARATOR
Intervention: trastuzumab RP switched to ABP 980
Number of subjects: 725
Study: 31409126

Group type: EXPERIMENTAL
Intervention: PARO intervention (n=21), exposed to PARO over a period of two weeks, three times per week
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group (n=18), read to aloud
Number of subjects: 39
Study: 28538111

Group type: EXPERIMENTAL
Intervention: Antisense oligonucleotide targeting ANGPTL3 mRNA (single dose: 20, 40, or 80 mg; multiple doses: 10, 20, 40, or 60 mg per week for 6 weeks)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 25320185

Group type: EXPERIMENTAL
Intervention: Protein intake of 0.2 to 2.0 g · kg(‐1) · d(‐1)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Current EAR and RDA based on nitrogen balance data
Number of subjects: 12
Study: 23438709

Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive therapy (MBCT)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Enhanced usual care (EUC)
Number of subjects: 96
Study: 20729765

Group type: EXPERIMENTAL
Intervention: Isoflavones (80 mg daily for 4 months)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo (for 4 months)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Isoflavones
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 19482863

Group type: EXPERIMENTAL
Intervention: Intramuscular interferon beta-1a (IFNbeta-1a) 30 mug once weekly
Number of subjects: 0
Study: 16549833

Group type: EXPERIMENTAL
Intervention: COL-3 (50 mg/d)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: COL-3 (100 mg/d)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: COL-3 (50 mg/d and 100 mg/d)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 75
Study: 12637625

Group type: EXPERIMENTAL
Intervention: Enfuvirtide plus an optimized background regimen of three to five antiretroviral drugs
Number of subjects: 501

Group type: COMPARATOR
Intervention: Optimized background regimen alone (control group)
Number of subjects: 501
Study: 11378851

Group type: EXPERIMENTAL
Intervention: Fenfluramine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Short variant of the 5-HT transporter promoter polymorphism
Number of subjects: 0

Group type: COMPARATOR
Intervention: 5-HT transporter promoter polymorphisms
Number of subjects: 0
Study: 9232087

Group type: EXPERIMENTAL
Intervention: Inhaled beclomethasone 200 micrograms/q.i.d.
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Inhaled budesonide 200 micrograms/q.i.d.
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group (not requiring steroids)
Number of subjects: 33
Study: 7953987

Group type: EXPERIMENTAL
Intervention: Ultrasound measurements using the Lunar Achilles system
Number of subjects: 0
Study: 3302053

Group type: EXPERIMENTAL
Intervention: 100 micrograms of ivermectin/kg
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: 150 micrograms of ivermectin/kg
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: 200 micrograms of ivermectin/kg
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study: 2676174

Group type: EXPERIMENTAL
Intervention: Propionyl-L-carnitine (PLC)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 12
Study: 31754063

Group type: EXPERIMENTAL
Intervention: Living with both biological parents
Number of subjects: 3907

Group type: EXPERIMENTAL
Intervention: Higher family life satisfaction
Number of subjects: 3907
Study: 31699109

Group type: EXPERIMENTAL
Intervention: cathodal tDCS (c-TDCS)
Number of subjects: 13

Group type: COMPARATOR
Intervention: sham stimulation
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: anodal tDCS (a-TDCS)
Number of subjects: 13

Group type: COMPARATOR
Intervention: gait initiation and backward balance perturbation
Number of subjects: 13